Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Sweden for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has been steadily growing due to various factors such as changing customer preferences, local special circumstances, and underlying macroeconomic factors.
Customer preferences: Patients in Sweden are increasingly opting for bronchodilator drugs that have fewer side effects and are more effective in treating respiratory diseases. They prefer drugs that are easy to use and have a quick onset of action. This has led to an increase in demand for combination bronchodilator drugs that provide both short-acting and long-acting relief.
Trends in the market: The trend towards combination bronchodilator drugs has been the major driver of growth in the Swedish market. This trend is expected to continue in the coming years as more patients become aware of the benefits of using combination drugs. Another trend in the market is the increasing use of inhalers as a mode of drug delivery. Inhalers are more convenient and provide targeted delivery of the drug to the lungs, resulting in better efficacy.
Local special circumstances: Sweden has a high prevalence of respiratory diseases, which has led to a high demand for bronchodilator drugs. The country also has a well-established healthcare system that provides easy access to these drugs. Additionally, the Swedish government has implemented policies to promote the use of generic drugs, which has led to increased competition and lower prices.
Underlying macroeconomic factors: The Swedish economy has been growing steadily, which has led to an increase in healthcare spending. This has resulted in increased funding for research and development of new bronchodilator drugs. The country also has a high level of education and awareness among its citizens, which has led to increased demand for effective treatments for respiratory diseases.In conclusion, the bronchodilator drugs market in Sweden is expected to continue growing due to changing customer preferences, local special circumstances, and underlying macroeconomic factors. The trend towards combination drugs and inhalers is expected to continue, and the government's policies promoting the use of generic drugs will continue to drive competition and lower prices.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
